secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105000
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC
-------------------------------------------------------------------

- Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.
- Cash and cash equivalents $18.2M as of June 30, 2025, down from $49.0M at Dec 31, 2024.
- BA3182 (EpCAM x CD3 TCE) Phase 1 dose-escalation ongoing; data readout expected 2H 2025.
- Oz-V (CAB-ROR2-ADC) shows 45% ORR (5/11) in 2L+ HPV+ OPSCC; FDA meeting planned in 3Q 2025.
- Company advancing partnering discussions; confident in closing at least one transaction in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/0000950170-25-105000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017025105000/bcab-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer